Immatics Investor Relations Material
Latest events
Study Update
Immatics
Q4 2024
27 Mar, 2025
Q3 2024
18 Nov, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Immatics N.V.
Access all reports
Immatics N.V. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of T cell redirecting immunotherapies aimed at treating cancer. The company's innovative approach combines the identification of true targets for cancer immunotherapies with the development of suitable T cell receptors. The company is headquartered in Tübingen, Germany, and its shares are listed on the Nasdaq.
Latest articles
)
MSCI: Indexing the World
The story of how MSCI has become the backbone of global finance through its indexes, powering decision-making across trillions in assets.
30 May 2025
)
A Purpose-Built AI Chat for Finance and IR Professionals
Quartr Pro's new AI chat lets IR and finance professionals ask anything across 13,000+ public companies and get instant answers.
27 May 2025
)
Costco Wholesale: The Model of Scalable Simplicity
Costco's rise from warehouse club to retail giant is built on low prices, scale efficiency, and a model designed for lasting customer value.
26 May 2025
Ticker symbol
IMTX
Country
🇺🇸 United States